Haemonetics Co. (HAE) Receives Average Rating of “Hold” from Brokerages
Shares of Haemonetics Co. (NYSE:HAE) have received a consensus rating of “Hold” from the nine analysts that are covering the firm. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $34.80.
Several equities research analysts have recently weighed in on HAE shares. TheStreet downgraded Haemonetics from a “b-” rating to a “c” rating in a research report on Monday, May 8th. Zacks Investment Research raised Haemonetics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 11th. Barrington Research downgraded Haemonetics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, February 7th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $42.00 target price on shares of Haemonetics in a research report on Monday, May 8th.
Shares of Haemonetics (NYSE:HAE) traded down 0.67% during mid-day trading on Friday, reaching $40.03. The company’s stock had a trading volume of 246,564 shares. Haemonetics has a 1-year low of $27.46 and a 1-year high of $43.62. The company’s 50-day moving average is $41.41 and its 200 day moving average is $39.64. The firm’s market capitalization is $2.08 billion.
Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Monday, May 8th. The medical instruments supplier reported $0.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.02. Haemonetics had a return on equity of 10.51% and a net margin of 1.79%. The firm had revenue of $228.10 million during the quarter, compared to the consensus estimate of $215.06 million. During the same quarter in the previous year, the business earned $0.37 earnings per share. The firm’s quarterly revenue was down 5.9% compared to the same quarter last year. On average, analysts expect that Haemonetics will post $1.60 earnings per share for the current year.
Large investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. bought a new stake in shares of Haemonetics during the first quarter valued at $179,000. State of Alaska Department of Revenue increased its stake in shares of Haemonetics by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 5,740 shares of the medical instruments supplier’s stock valued at $232,000 after buying an additional 130 shares during the last quarter. Trexquant Investment LP bought a new stake in shares of Haemonetics during the fourth quarter valued at $269,000. AXA bought a new stake in shares of Haemonetics during the first quarter valued at $292,000. Finally, Kirr Marbach & Co. LLC IN increased its stake in shares of Haemonetics by 1.1% in the first quarter. Kirr Marbach & Co. LLC IN now owns 7,230 shares of the medical instruments supplier’s stock valued at $293,000 after buying an additional 80 shares during the last quarter. 99.43% of the stock is owned by institutional investors.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Co. and related companies with MarketBeat.com's FREE daily email newsletter.